In recent years, the use of flash glucose monitoring (FGM) has been established as a reliable method for measuring interstitial glucose, which, in addition, provides new tools for glycaemic control in diabetes patients.1

The use of FGM in patients in real life has demonstrated an improvement in different glycaemic variables, such as a reduction in HbA1c, a reduction of time in hypoglycaemia and hyperglycaemia, as well as an increase in time in range.2

Moreover, the recent improvement in the new glycaemic parameters through interstitial glucose monitoring (IGM) has been correlated with a reduced risk in microvascular and macrovascular complications.3

The efficacy of FGM in achieving greater glycaemic control has been shown to be directly related with the number of scans, involvement and the adequate use of the system by the patient.4 In this regard, the establishment of specific diabetes education therapy protocols for learning how to use and interpret the system data have proven to be a necessary strategy.5 Conversely, the use of FGM has been related with an improvement in the perception of quality of life by patients.6

Currently, the funding of FGM by the National Health System is applied fundamentally to persons with type I diabetes (DM1),7 although preliminary data would seem to support the efficacy thereof in certain type II diabetes (DM2) subgroups.8

One of the additional advantages of using FGM Is based on the capacity of these systems to share glycaemic results, remotely and in real time, with the healthcare professionals and family members/caregivers through specific platforms (Libreview®). This tool has facilitated virtual consultations, allowing, In turn, the detailed analysis of the outpatient glucose profile by the diabetes care team and the patient.

As a result of the SARS-CoV-2 pandemic, and thanks partly to these devices, the working methodology in diabetes therapeutic education consultations has been modified, to include teletraining, as a new safe and reliable distance training tool, thus making it possible to maintain close contact with the patient.9

Indeed, telemedicine platforms have been shown to be feasible and effective for providing care to diabetes patients, although it is advisable to take precautions, which include meticulous adaptation to the institution, the physician and the population of patients attended, to ensure that the virtual care has the greatest possible impact.10

The aim of this study was to evaluate the degree of metabolic control and satisfaction in a group of patients with DM1 attended by means of online consultation on diabetes therapeutic education for training in FGM, both at baseline and three months after the implementation thereof, as well as to compare the results obtained with a cohort of DM1 patients with face-to-face training in FGM.